Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

@article{Capper2011AssessmentOB,
  title={Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody},
  author={David Capper and Matthias Preusser and Antje Habel and Felix Sahm and Ulrike Ackermann and Genevieve Schindler and Stefan Pusch and Gunhild Mechtersheimer and H. Zentgraf and Andreas von Deimling},
  journal={Acta Neuropathologica},
  year={2011},
  volume={122},
  pages={11-19}
}
Activating mutations of the serine threonine kinase v-RAF murine sarcoma viral oncogene homolog B1 (BRAF) are frequent in benign and malignant human tumors and are emerging as an important biomarker. Over 95% of BRAF mutations are of the V600E type and specific small molecular inhibitors are currently under pre-clinical or clinical investigation. BRAF mutation status is determined by DNA-based methods, most commonly by sequencing. Here we describe the development of a monoclonal BRAF V600E… 
Detection of the BRAF V600E Mutation in Colon Carcinoma: Critical Evaluation of the Imunohistochemical Approach
TLDR
Although VE1 antibody can be useful in the screening of colon carcinomas for BRAF V600E-mutant proteins, molecular genetic confirmation is always necessary for mutation diagnosis and only strong positivity should be considered when using the VE 1 antibody and Leica Bond-Max automated immunohistochemistry.
Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma.
BRAF V600E Mutation Across Multiple Tumor Types: Correlation Between DNA-based Sequencing and Mutation-specific Immunohistochemistry
TLDR
Analysis of multiple tumor types including melanoma, colorectal carcinoma, papillary thyroid cancer, hairy cell leukemia, and Langerhans cell histiocytosis using both DNA-based sequencing and the BRAF V600E mutation–specific antibody shows a high degree of concordance between the 2 methods.
Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma
TLDR
Findings from the current study support the potential use of immunohistochemistry as an ancillary screening tool to assess the BRAFV600E mutation status in primary cutaneous melanoma.
BRAF V600E mutation-specific antibody: A review.
TLDR
Clinopathologic characteristics associated with BRAF-mutant tumors will be highlighted, and the prognostic and predictive implications of a BRAF V600E mutation will be discussed with a focus on melanoma, thyroid carcinoma and colorectal carcinoma.
Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
TLDR
It is indicated that VE1 antibody-based IHC analysis demonstrated high sensitivity and specificity to detect BRAF V600E-mutated lung ADCs in tissues from primary or metastatic sites.
BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods
TLDR
The high concordance rate of PCR and immunohistochemical methods in determining BRAF status suggests that Immunohistochemistry is potentially a viable, cost-effective alternative to PCR testing and suitable as a screening test for the BRAF mutation.
...
...

References

SHOWING 1-10 OF 34 REFERENCES
NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing
TLDR
The separate genotypes of BRAF and NRAS were associated with differences in several key clinical and pathological parameters, indicating differences in the biology of melanoma tumours with different proto-oncogene mutations.
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls
TLDR
The tumor heterogeneity observed in some patients indicates that it should be more appropriate to perform KRAS genotyping on metastases if sample is available, and the development of quality control scheme for molecular pathology, especially because of DNA damages induced by formalin fixation.
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma.
TLDR
It is shown that a somatic mutation of BRAF, V599E, is the most common genetic change in PTCs, and represents a unique paradigm of human tumorigenesis through mutation of three signaling effectors lying in tandem.
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.
TLDR
The apparent restriction of these BRAF and KRAS mutations to low-grade serous ovarian carcinoma and its precursors suggests that low- grade and high-grade ovarian serous carcinomas develop through independent pathways.
High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi.
TLDR
The results strongly suggest that UV light is not necessarily required for the acquisition of the BRAF(V600E) mutation, and suggest that non-mutagenic effects of UV light to melanocytes may be more important in the nevogenesis.
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
TLDR
BRAF wild-type is required for response to panitumumab or cetuximab and could be used to select patients who are eligible for the treatment and should be used for selection.
Recurrent BRAF mutations in Langerhans cell histiocytosis.
TLDR
High prevalence, recurrent BRAF mutations in LCH indicate that it is a neoplastic disease that may respond to RAF pathway inhibitors, and the oncogenic BRAF V600E mutation is identified.
High frequency of BRAF mutations in nevi
TLDR
It is suggested that mutational activation of the RAS/RAF/MAPK pathway in nevi is a critical step in the initiation of melanocytic neoplasia but alone is insufficient for melanoma tumorigenesis.
Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors
TLDR
Investigation of the capability of this antibody to differentiate wild type and mutated IDH1 protein in central nervous system (CNS) tumors by Western blot and immunohistochemistry finds the ability of mIDH1R132H to detect single infiltrating tumor cells intriguing.
...
...